Skip to main content

Table 3 Factors associated with receiving triage among HPV screen positive women in Nicaragua in 2017

From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment

 Not Triaged
(N = 3120)
Triaged
(N = 3656)
n (%)n (%)Unadjusted Prevalence ORa (95% CI)Adjusted Prevalence ORb (95% CI)Triage Ratio
Province
 Carazo1062 (54.1)900 (45.9)RefRefRef
 Chinandega1482 (48.9)1546 (51.1)1.23 (1.10–1.38)*1.23 (1.09–1.38)*1.11
 Chontales576 (32.3)1210 (67.8)2.48 (2.17–2.81)*2.78 (2.43–3.19)*1.48
Age, years
 < 3028 (50.0)28 (50.0)RefRefRef
 30–391812 (46.3)2103 (53.7)1.16 (0.68–1.97)1.18 (0.69–2.02)1.07
 40–49747 (43.3)979 (56.7)1.31 (0.77–2.23)1.36 (0.79–2.34)1.13
 50–59512 (49.2)528 (50.8)1.03 (0.60–1.77)1.07 (0.62–1.86)1.02
 60+19 (54.3)16 (45.7)0.84 (0.36–1.96)0.89 (0.38–2.11)0.91
 Unknown2 (50.0)2 (50.0)1.00 (0.13–7.60)0.63 (0.08–4.97)1.00
HPV Screening Modality
 Self-collected3019 (45.9)3559 (54.1)RefRefRef
 Provider-collected27 (24.1)85 (75.9)2.67 (1.73–4.13)*2.82 (1.82–4.39)*1.40
 Unknown74 (91.9)12 (14.0)0.14 (0.07–0.25)*0.07 (0.04–0.14)*0.26
  1. Abbreviations: HPV Human papilloma virus, CI confidence interval, OR odds ratio, Ref Reference category
  2. * P values < 0.001
  3. aUnadjusted prevalence odds ratio for the association between each risk factor and receiving triage (either Pap or VIA)
  4. bAdjusted prevalence odds ratio for all the listed factors